Censo Biotechnologies attending Cancer Research UK's inaugural Brain Tumour Conference
The inaugural Cancer Research UK (CRUK) Brain Tumour Conference will unite the brightest minds in cancer research to discuss and debate some of the greatest issues in the field. The multidisciplinary programme combines expertise from across the breadth of brain tumour research, together with insights from allied disciplines, to spark new opportunities for collaborative research.
During each day of the conference there will be networking opportunities and Poster Sessions - this will include 'Patient-Derived Brain Tumour iPSCs: Models for Investigating Glioma Stemness & Drug Discovery' with contribution from Censo Biotechnologies, in association with the University of Leeds.
Self-renewal capability (a stem cell-like feature), when unregulated, has been implicated in glioma treatment resistance and tumour recurrence. Drugs that eliminate tumour cells possessing this malignant characteristic are urgently needed. It remains, however, an experimental challenge to link heterogeneous glioma genotypes to drug response at scale.
To this end, University of Leeds successfully derived patient-specific induced pluripotent stem cell (iPSC) models from both low- (LGG) and high-grade gliomas (HGG) and developed an initial drug discovery application. Censo Biotechnologies was involved in the RNAseq and in vitro assay data and is in the process of deriving iPSC from HGG only.
The iPSC models may uncover genetic mutations and regulatory networks underlying glioma stem cell self-renewal, and provide a basis for industrial-scale drug discovery. Here we have successfully implemented the first stages towards this development (in a 96-well assay format). Ultimately, our iPSC-based approach may enable personalised precision medicine strategies against glioma.